Clinical validation of the tempus xT next-generation targeted oncology sequencing assay
Metrics: PDF 708 views | HTML 1141 views | ?
Nike Beaubier1, Robert Tell1, Denise Lau1, Jerod R. Parsons1, Stephen Bush1, Jason Perera1, Shelly Sorrells1, Timothy Baker1, Alan Chang1, Jackson Michuda1, Catherine Iguartua1, Shelley MacNeil1, Kaanan Shah1, Philip Ellis1, Kimberly Yeatts1, Brett Mahon1, Timothy Taxter1, Martin Bontrager1, Aly Khan1, Robert Huether1, Eric Lefkofsky1 and Kevin P. White1
1Tempus Labs Inc., Chicago, IL 60654, USA
Nike Beaubier, email: firstname.lastname@example.org
Kevin P. White, email: email@example.com
Keywords: tumor profiling, next-generation sequencing assay validation
Received: August 03, 2018 Accepted: February 03, 2019 Published: March 22, 2019
We developed and clinically validated a hybrid capture next generation sequencing assay to detect somatic alterations and microsatellite instability in solid tumors and hematologic malignancies. This targeted oncology assay utilizes tumor-normal matched samples for highly accurate somatic alteration calling and whole transcriptome RNA sequencing for unbiased identification of gene fusion events. The assay was validated with a combination of clinical specimens and cell lines, and recorded a sensitivity of 99.1% for single nucleotide variants, 98.1% for indels, 99.9% for gene rearrangements, 98.4% for copy number variations, and 99.9% for microsatellite instability detection. This assay presents a wide array of data for clinical management and clinical trial enrollment while conserving limited tissue.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.